<SEC-DOCUMENT>0001737287-24-000019.txt : 20240314
<SEC-HEADER>0001737287-24-000019.hdr.sgml : 20240314
<ACCEPTANCE-DATETIME>20240314161020
ACCESSION NUMBER:		0001737287-24-000019
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240314
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240314
DATE AS OF CHANGE:		20240314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		24750186

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>allo-20240314.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20240314</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="allo-20240314.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-14</xbrli:startDate><xbrli:endDate>2024-03-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib62ee2d9da4541feba09c191ab4cad99_1"></div><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 14, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_______________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Allogene Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38693</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="9" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">457-2700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:3.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">on&#160;which&#160;registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ALLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b&#8211;2 of this chapter).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ib62ee2d9da4541feba09c191ab4cad99_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2024, Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2023 in the press release attached hereto as Exhibit&#160;99.1 and incorporated herein by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item&#160;2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="ib62ee2d9da4541feba09c191ab4cad99_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Exhibits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20240314xexx9912023pr.htm">Press Release of the Company, dated March 14, 2024.</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ib62ee2d9da4541feba09c191ab4cad99_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.955%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALLOGENE THERAPEUTICS, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Chang, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: March 14, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>allo-20240314xexx9912023pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9cf7d946af2345bea5a0e9af534b6fcf_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt"><img alt="g725933allogenea06.jpg" src="g725933allogenea06.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:176px"></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Results and Business Update</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Large B-Cell Lymphoma (LBCL)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Start-Up Activities Underway</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#59; Enrollment to Begin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Mid-2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Cema-cel Phase 1 ALPHA2 Trial in Relapsed&#47;Refractory Chronic Lymphocytic Leukemia (CLL)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Enrolling Patients with Initial Data Projected YE 2024 </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">ALLO-329 in Autoimmune Disease (AID)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Differentiated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Next-Generation CD19 Dagger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Program Designed for AID will Focus on Eliminating Lymphodepletion and Meeting Demand&#59; </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1 Clinical Trials in Early 2025</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">ALLO-316 Phase 1 TRAVERSE Trial in Renal Cell Carcinoma (RCC)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Update on Safety Algorithm Planned for Publication in Q2 2024 </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Ended 2023 with $448.7 Million in Cash, Cash Equivalents and Investments&#59; Reiterates Cash Runway Projection into 2026</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Conference Call and Webcast Scheduled for Today at 2&#58;00 PM PT&#47;5&#58;00 PM ET</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SOUTH SAN FRANCISCO, Calif.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, March </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene Therapeutics, Inc.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Nasdaq&#58; ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T&#8482;) products for cancer and autoimmune disease, today provided a corporate update and reported financial results for the quarter and year ended December 31, 2023.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;We are more enthusiastic than ever about the potential for allogeneic CAR T to transform the field,&#8221; said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. &#8220;From our innovative ALPHA3 trial which is designed to embed cema-cel as part of a curative first-line regimen for patients with large B cell lymphoma, to specifically creating a CAR T that can meet the unique needs of patients with autoimmune disease and reduce reliance on lymphodepletion, our development approach focuses on the distinctive attributes of an off-the-shelf alternative and creates an advantage for our AlloCAR T&#8482; programs.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Core Program Updates</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cema-Cel&#58; Pivotal ALPHA3 1L Consolidation Trial in Large B Cell Lymphoma (LBCL)</font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company continues to focus on the development of its investigational product cemacabtagene ansegedleucel, or cema-cel (previously known as ALLO-501A) as part of the first line (1L) treatment plan for LBCL patients who are likely to relapse following 1L chemoimmunotherapy.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This innovative trial takes advantage of the unique attributes of cema-cel, the only allogeneic cell therapy product with Phase 1 data comparable to that of an autologous therapy. With off-the-shelf availability and convenience, cema-cel will be administered as a one-time infusion immediately upon detection of minimal residual disease (MRD) at the completion of six cycles of R-CHOP or equivalent 1L chemoimmunotherapy. The potential outcome of this consolidation treatment could improve the cure rate and uniquely position cema-cel to become the standard &#8220;7</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> cycle&#8221; of frontline treatment available to all eligible patients with MRD.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The design of the ALPHA3 1L consolidation trial builds upon the results demonstrated in the cema-cel Phase 1 ALPHA2 trial and will leverage an investigational, cutting-edge diagnostic test for MRD developed by Foresight Diagnostics. ALPHA3 will randomize approximately 230 patients who are in clinical remission but remain MRD positive at the end of standard 1L chemoimmunotherapy to either consolidation with cema-cel or the current standard of care, observation, which means to &#8220;watch and wait&#8221; for the disease to relapse. The primary endpoint of the ALPHA3 trial is event free survival (EFS). The trial will initially test two lymphodepletion regimens (one with standard fludarabine and cyclophosphamide plus ALLO-647 and one without ALLO-647). One lymphodepletion arm will be discontinued following a planned interim analysis in mid-2025 designed to select the most appropriate regimen for this patient population.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Start-up activities for the ALPHA3 trial are underway and the trial is expected to begin in mid-2024. The ALPHA3 trial will be conducted in a wide array of cancer treatment centers, including community cancer centers where most earlier line patients seek care.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cema-Cel&#58; Phase 1 ALPHA2 Trial in Chronic Lymphocytic Leukemia (CLL)</font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter, the Company began enrollment in the ALPHA2 trial of the investigational product cema-cel in patients with relapsed&#47;refractory (r&#47;r) CLL. While recent autologous CD19 CAR T data has been a positive step for patients with relapsed&#47;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">refractory (r&#47;r) CLL, T cell dysfunction and high circulating leukemia burden often found in patients with CLL, make the isolation of functional T cells for autologous CAR T manufacturing difficult. As a result, this trial has been driven by investigator enthusiasm for an allogeneic CAR T to potentially boost the curative power of CAR T.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Initial data readout from Phase 1 ALPHA2 CLL cohort (n&#61;12) is projected by year-end 2024.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ALLO-329&#58; CD19 Dagger</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> in Autoimmune Disease (AID)</font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has applied its deep understanding of CAR T research and development to design next-generation allogeneic CAR T investigational products that the Company believes can sustain the scale of the AID market while also meeting the unique requirements for these patients where they seek care.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ALLO-329, the Company&#8217;s first AlloCAR T investigational product for AID, incorporates the Dagger</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> technology which is intended to reduce or eliminate the need for lymphodepletion while targeting CD19+ B-cells and CD70+ activated T-cells, both of which play a role in AID.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of its overarching AID 2.0 platform, the Company also announced a non-exclusive, global gene editing licensing agreement with Arbor Biotechnologies, Inc. for use of their proprietary CRISPR-based gene-editing technology.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ALLO-329 is expected to enter Phase 1 clinical trials in early 2025.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ALLO-316&#58; TRAVERSE Trial in Renal Cell Carcinoma (RCC)</font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Building upon the field&#8217;s understanding of how certain drugs can act as a &#8220;safety key&#8221; to mitigate treatment-associated adverse events without compromising CAR T function or efficacy, the Company has developed and implemented a diagnostic and treatment algorithm in its solid tumor trial that may mitigate the treatment-associated hyperinflammatory response without compromising the CAR T function needed to eradicate solid tumors with ALLO-316 in renal cell carcinoma (RCC).</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Details on this potentially cornerstone discovery in the Phase 1 TRAVERSE trial is planned for a publication in Q2 2024. A more comprehensive data update from the ongoing trial with the updated protocol is planned for later in 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Financial Updates</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As noted in the February 16, 2024 press release, the Company has now issued restated financials for the years ended December 31, 2020, 2021 and 2022 and interim quarters during 2022 and 2023 due to non-cash accounting adjustments associated with the December 2020 formation of the Allogene Overland Biopharm joint venture in Asia. These restated financial statements have no impact on the Company&#8217;s cash, cash equivalents and marketable investments, cash runway or business operations.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023 Fourth Quarter and Year-End Financial Results</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Research and development expenses were $54.7 million for the fourth quarter of 2023, which includes $7.0 million of non-cash stock-based compensation expense. For the full year of 2023, research and development expenses were $242.9 million, which includes $31.9 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">General and administrative expenses were $17.2 million for the fourth quarter of 2023, which includes $8.2 million of non-cash stock-based compensation expense. For the full year of 2023, general and administrative expenses were $71.7 million, which includes $34.0 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Net loss for the fourth quarter of 2023 was $85.8 million, or $0.51 per share, including non-cash stock-based compensation expense of $15.2 million and $13.2 million in non-cash impairment of long-lived asset expense. For the full year of 2023, net loss was $327.3 million, or $2.09 per share, including non-cash stock-based compensation expense of $66.0 million and $13.2 million in non-cash impairment of long-lived asset expense.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The Company had $448.7&#160;million in cash, cash equivalents, and investments as of December 31, 2023. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2024 Financial Guidance</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The Company expects a decrease in cash, cash equivalents, and investments of approximately $190 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in 2024.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Based on current assumptions, the Company continues to expect its cash runway to fund operations into 2026. GAAP Operating Expenses are expected to be approximately $280 million, including estimated non-cash stock-based compensation expense of approximately $60 million. These estimates exclude any impact from potential business development activities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Conference Call and Webcast Details</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene will host a live conference call and webcast today at 2&#58;00 p.m. Pacific Time &#47; 5&#58;00 p.m. Eastern Time to discuss financial results and provide a business update. If you would like the option to ask a question on the conference call, please use </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">this link</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to register. Upon registering for the conference call, you will receive a personal PIN to access the call, which will identify you as the participant and allow you the option to ask a question. The listen-only webcast will be made available on the Company's website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">About Allogene Therapeutics</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene Therapeutics, with headquarters in&#8239;South San Francisco, is a clinical-stage&#8239;biotechnology company pioneering the development of allogeneic chimeric antigen receptor T&#8239;cell (AlloCAR T&#8482;) products for cancer and autoimmune disease. Led by a management team with significant&#8239;experience in cell therapy, Allogene is developing a pipeline of &#8220;off-the-shelf&#8221; CAR T cell product&#8239;candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at&#8239;greater scale to more patients. For more information, please visit&#8239;www.allogene.com, and follow &#64;AllogeneTx.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cautionary Note on Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as &#34;predicts,&#34; &#8220;projects,&#8221; &#34;believes,&#34; &#34;potential,&#34; &#34;proposed,&#34; &#34;continue,&#34; &#34;estimates,&#34; &#34;anticipates,&#34; &#34;expects,&#34; &#34;plans,&#34; &#34;intends,&#34; &#34;designed to, &#34; &#34;can, &#34;, &#34;become,&#34; &#34;build, &#34; &#34;may,&#34; &#34;could,&#34; &#34;might,&#34; &#34;will,&#34; &#34;should&#34; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things&#58; ALPHA3 being a pivotal trial&#59; the design of ALPHA3&#59; the potential of ALPHA3 to be administered as a one-time infusion&#59; the potential for cema-cel to become the standard of frontline treatment available to eligible patients with MRD&#59; the potential for ALPHA3 to improve cure rates&#59; plans to administer cema-cel in community cancer centers in the ALPHA3 trial&#59; use of a Foresight Diagnostics test in ALPHA3 and its anticipated sensitivity&#59; the potential for cema-cel&#8217;s safety profile to further improve in patients with no radiological evidence of disease&#59; the potential outcomes of ALPHA3&#59; the pace, timing and extent to which we may initiate or enroll patients in our clinical trials or release data from such trials including ALPHA2, ALPHA3, ALLO-329, and TRAVERSE trials&#59; &#59; statements related to ALPHA2, including expected enrollment timing, expected timing for data, the potential to isolate functional T cells in manufacturing allogeneic CAR T less difficult, and the potential to boost the curative potential of CAR T&#59; clinical outcomes, which may materially change as more patient data become available&#59; the design and potential benefits of our Dagger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> technology including the ability to reduce or eliminate the need for lymphodepletion, and the expected benefits therefrom, to treat autoimmune disease, and our plans to deploy the Dagger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> technology&#59; the potential for our product candidates to be approved&#59; the potential benefits of AlloCAR T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products&#59; the ability of our product candidates to treat various stages and types of cancers including hematological and solid tumors or to treat autoimmune disease&#59; the potential ability of our diagnostic and treatment algorithm to address emerging safety findings or mitigate treatment-associated hyperinflammatory response without compromising CAR T function&#59; our expectation that our cash runway extends into 2026&#59; financial guidance for 2024&#59; the modes of action or the biologic impacts of our product candidates&#59; the potential for off-the-shelf CAR T products, including its potential to transform the field&#59; and other statements related to future events or conditions. Various factors may cause material differences between Allogene&#8217;s expectations and actual results, including, risks and uncertainties related to&#58; changes in the macroeconomic environment or industry that impact our business&#59; competition&#59; risks related to third-party performance&#59; our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval&#59; the limited nature of the Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trial&#59; preliminary results may not be indicative of results that may be observed in the future&#59; our ability to maintain intellectual property rights necessary for the continued development of our product candidates, including pursuant to our license agreements&#59; our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval or limit their commercial potential&#59; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials or require additional clinical trials&#59; we may encounter difficulties enrolling patients in our clinical trials, including ALPHA2, ALPHA3, ALLO-329 and TRAVERSE trials&#59; there is no guarantee that Foresight will successfully develop an MRD assay for use as a companion diagnostic with cema-cel, and without a companion diagnostic the prospects for cema-cel could be materially and negatively impacted&#59; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization&#59; challenges with manufacturing or optimizing manufacturing of our product candidates or any companion diagnostic for use with our product candidates&#59; and our ability to obtain additional financing to develop our product candidates and implement our operating plans. These and other risks are discussed in greater detail in Allogene&#8217;s filings with the SEC, including without limitation under the &#8220;Risk Factors&#8221; heading in its Annual Report on Form 10-K for the year ended December 31, 2023 being filed with the SEC today. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Caution should be exercised regarding statements comparing autologous CAR T data. There are differences in the clinical trial design, patient populations, published data, follow-up times and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AlloCAR T&#8482; and Dagger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> are trademarks of Allogene Therapeutics, Inc.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene&#8217;s investigational </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AlloCAR T&#8482; </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">oncology products utilize Cellectis technologies. ALLO-501 and cemacabtagene ansegedleucel (previously known as ALLO-501A) are anti-CD19 AlloCAR T&#8482; investigational </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">products being jointly developed </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The anti-CD70 AlloCAR T </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> program.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9cf7d946af2345bea5a0e9af534b6fcf_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited&#59; in thousands, except share and per share data)</font></div><div id="i9cf7d946af2345bea5a0e9af534b6fcf_7"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,661&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,419&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,387&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,224&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,002&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,305&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,245&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,245&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,130&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,421&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,832&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,692&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,109)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,395)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,737)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335,536)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,265&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,757&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,307&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,566&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,934)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,637)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,835)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,444)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(880)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,878)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,778)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,275)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,265)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(340,414)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.51)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.67)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.09)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.38)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in computing net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,335,828&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,149,240&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,931,778&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,147,165&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="i9cf7d946af2345bea5a0e9af534b6fcf_10"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED BALANCE SHEET DATA</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and investments</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,697&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,471&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642,837&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821,579&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,604&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,697&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512,233&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,882&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allogene Media&#47;Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christine Cassiano</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EVP, Chief Corporate Affairs &#38; Brand Strategy Officer</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Christine.Cassiano&#64;allogene.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>allo-20240314.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7b726979-3177-477a-bb62-418d48ff6507,g:0d743949-81bc-4f86-8cab-567197e26494-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:allo="http://allogene.com/20240314" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20240314">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20240314_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20240314_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://allogene.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>allo-20240314_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7b726979-3177-477a-bb62-418d48ff6507,g:0d743949-81bc-4f86-8cab-567197e26494-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_3a9cfc8b-632f-4601-b8f6-49d0f1dfe014_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bcfe3257-2140-4ddc-8ca0-84df285353ad_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_97501e51-2472-4e59-8dfe-952b7ec47709_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_af14317e-a182-48ab-b136-bba98fbaac40_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_69322623-a8f0-414f-bd23-497cb72f8f56_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_97a56b71-6540-4bbb-8400-1d9be704eb24_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_64171ac4-f9ea-449d-96d5-23e3e8c1e671_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d7cfe5fe-f1f5-45f4-a580-13ff2e9c96db_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2d3289ea-3b89-44f7-9ca1-3dd8ee42ca33_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4d986816-e531-4a7c-8674-eaf3254311c8_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_04dacddb-0294-4235-9eed-4aae1d7c82fa_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_bbab2f16-fbe7-48f8-bbd0-a25b3191a4aa_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_e9e96eca-4a75-4993-9c6f-add1d56a06f4_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2fa88912-5c9d-4a74-a574-50ae4f7a3896_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_45ff6b58-cdcb-4ed3-8d88-0fe9c758d6c9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_588ea82f-7949-4505-87c4-b7fd9cce72fe_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_72ff6182-f788-4c98-898c-63769a418c46_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f5e75efc-71d7-4e35-a056-60b5610a3850_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_42bcadd2-4131-4cfe-8870-5cd404e9ed24_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_afe21732-cdb2-4401-8b78-66ae8f77144c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fa466746-bc1d-4aa0-a5e1-264369a556e4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0a272292-90ba-42a3-9cb0-0800c3131bf0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4f243aa4-88bf-4ee7-967f-c560cc7575a0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>allo-20240314_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7b726979-3177-477a-bb62-418d48ff6507,g:0d743949-81bc-4f86-8cab-567197e26494-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="allo-20240314.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2bee5e30-8a28-450e-b9dd-e5a67e957234" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_DocumentType_2bee5e30-8a28-450e-b9dd-e5a67e957234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_74766dfa-f6ae-41c5-af70-5d77adabe2e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_DocumentPeriodEndDate_74766dfa-f6ae-41c5-af70-5d77adabe2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_59f9ceee-8adb-43ea-9a72-0becc7aca820" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityRegistrantName_59f9ceee-8adb-43ea-9a72-0becc7aca820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_edc4dc1b-36cf-4f37-8573-78c150660bc4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityCentralIndexKey_edc4dc1b-36cf-4f37-8573-78c150660bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a0414faf-2c8b-4266-85e2-6a98f1e51d0b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_AmendmentFlag_a0414faf-2c8b-4266-85e2-6a98f1e51d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8cc55b11-f760-43a8-80f9-a2acdadfbcd9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8cc55b11-f760-43a8-80f9-a2acdadfbcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d0fa133b-2022-4a01-88f6-5f687343ad01" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityFileNumber_d0fa133b-2022-4a01-88f6-5f687343ad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6b92216a-0537-4cfb-a8fe-043ca1b169ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityTaxIdentificationNumber_6b92216a-0537-4cfb-a8fe-043ca1b169ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2400619e-ba19-457e-8f7b-d500ec4dea06" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityAddressAddressLine1_2400619e-ba19-457e-8f7b-d500ec4dea06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_91bee18b-9e2c-48a4-99e4-605935b46e18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityAddressCityOrTown_91bee18b-9e2c-48a4-99e4-605935b46e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5fedcbf4-2757-4df4-8dbc-cacc5a06628a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityAddressStateOrProvince_5fedcbf4-2757-4df4-8dbc-cacc5a06628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4555b640-9869-4ca6-8221-3d358a1eb0e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityAddressPostalZipCode_4555b640-9869-4ca6-8221-3d358a1eb0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9491a703-08db-4f9f-8758-6b9ee399d688" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_CityAreaCode_9491a703-08db-4f9f-8758-6b9ee399d688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cdede05d-365e-454f-9122-6cce257ca046" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_LocalPhoneNumber_cdede05d-365e-454f-9122-6cce257ca046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a4696bdb-b103-4a21-ab9c-fe3e5238a15b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_WrittenCommunications_a4696bdb-b103-4a21-ab9c-fe3e5238a15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7c82f1dc-4de8-48a8-a62c-f0b914d9f934" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_SolicitingMaterial_7c82f1dc-4de8-48a8-a62c-f0b914d9f934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_36e2c069-19f4-45af-8d6c-766c79e8283e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_PreCommencementTenderOffer_36e2c069-19f4-45af-8d6c-766c79e8283e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_87b8780d-5799-421a-8f80-762c0e51c7e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_87b8780d-5799-421a-8f80-762c0e51c7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_aa527b96-30b0-497a-b432-7f43691aa655" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_Security12bTitle_aa527b96-30b0-497a-b432-7f43691aa655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a03d3b84-4798-4865-a166-2c12d9b36141" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_TradingSymbol_a03d3b84-4798-4865-a166-2c12d9b36141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b3db6c1c-12c1-499a-9cb6-25ff557f617e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_SecurityExchangeName_b3db6c1c-12c1-499a-9cb6-25ff557f617e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1b327198-29f6-4fe3-8487-35f06cdf72bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a1673770-c001-428f-b74f-c921182d48e2" xlink:to="loc_dei_EntityEmergingGrowthCompany_1b327198-29f6-4fe3-8487-35f06cdf72bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g725933allogenea06.jpg
<TEXT>
begin 644 g725933allogenea06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P ,P# 2(  A$! Q$!_\0
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M[Z7_ .AWU0_\%+#_ ,;^OV>?^O;0O_3A?5)^WC,L/_!Q/\"6;[OD:2OXF2^
M_G6U/['_ %[9PXQ_O,1_V%4_RB4_^"H!US_@H7_P5E\"_LTMJEWH_@?P^(;W
M4!:N"TTKVYNKBX*GY3(D 6&(L&\LO(P!W$5]H>*O^"-O[./B;X3R>$5^&>BZ
M7;^08H=3L%,>K6[8P)1='=(S@\_O"RD]5()%?'G_  5N\#^,/V%/^"B'@O\
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MPA^%\]QI%E8QB=EG,.P/$HB#,K7$^6DD7#-'"B[AM3'M/A^5HO\ @YYO]O\
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@]/Q^XYL3_9<:3A@:/LVY75E9*-MG[SN[];*^NU[+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249855363808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 14,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ 2H%N6)>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $J!;EC9"I1S:00  -$0   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !*@6Y8GZ ;\+$"  #B#   #0              @ &M#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( $J!;EB7BKL<P    !,"   +
M  "  8D/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $J!;E@<.&7J/P$  #P"
M   /              "  7(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !*@6Y8)!Z;HJT   #X 0  &@              @ '>$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !*@6Y899!YDAD!  #/ P
M$P              @ '#$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"   -%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="allo-20240314.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="allo-20240314.htm">allo-20240314.htm</File>
    <File>allo-20240314.xsd</File>
    <File>allo-20240314_lab.xml</File>
    <File>allo-20240314_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "allo-20240314.htm": {
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20240314",
   "dts": {
    "inline": {
     "local": [
      "allo-20240314.htm"
     ]
    },
    "schema": {
     "local": [
      "allo-20240314.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20240314_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20240314_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://allogene.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "allo-20240314.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "allo-20240314.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001737287-24-000019-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-24-000019-xbrl.zip
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M?/6,ZT-KL^(&QN_O7JV?R9;_J//=J_\!4$L#!!0    ( $J!;E@K5>,=O08
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MEF!C$POM?>R+,:\XPF=G\CI, %>]T[/?>@UV(J,X8:>P!MNW3]^#, _BT)>
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M<?>:!R0C$%CX[%DN1Y9%?S6N:DK9*-M@4=Y*&8RN<$(5L?A ]*C\_SYRDO'
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M_I:E^RC]'(3N%/X9)6/_X_\#4$L! A0#%     @ 2H%N6*R_<:NA#@  =V(
M !$              ( !     &%L;&\M,C R-# S,30N:'1M4$L! A0#%
M  @ 2H%N6 L7.86# @  Q0<  !$              ( !T X  &%L;&\M,C R
M-# S,30N>'-D4$L! A0#%     @ 2H%N6%I?C;TI"@  >%4  !4
M     ( !@A$  &%L;&\M,C R-# S,31?;&%B+GAM;%!+ 0(4 Q0    ( $J!
M;E@K5>,=O08  #,Q   5              "  =X;  !A;&QO+3(P,C0P,S$T
M7W!R92YX;6Q02P$"% ,4    " !*@6Y8+D2-YPPD  "(&0$ '@
M    @ '.(@  86QL;RTR,#(T,#,Q-'AE>'@Y.3$R,#(S<'(N:'1M4$L%!@
0   %  4 4 $  !9'      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>allo-20240314_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="allo-20240314.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2024-03-14</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001737287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-03-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38693</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">457-2700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
